GlassScriptPhysician profile
Mohammad Abu Sheikha
NPI 1629590088
$2,552.76
in general payments reported to CMS, 2019-2025
19 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $207 · 2023: $55.96 · 2024: $1,654 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,345.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,345.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $380.75 | 2024-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $338.72 | 2022-2024 | Jardiance |
| Abiomed | $325.13 | 2024-2025 | Impella |
| Edwards Lifesciences Corporation | $203.43 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $196.71 | 2022-2025 | Camzyos |
| Medtronic, INC. | $174.15 | 2024-2025 | Cobalt Dr Mri Surescan, Azure Xt Dr Mri Surescan, Omniasecure Mri Surescan |
| Heartflow, INC. | $169.79 | 2024 | |
| Lantheus Medical Imaging, INC. | $162.34 | 2024 | |
| Abbott Laboratories | $114.64 | 2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Biotronik INC. | $112.47 | 2024-2025 | Biomonitor, Acticor 7 Vr-T Dx, Amvia Edge |
| Pfizer INC. | $85.35 | 2024-2025 | |
| Novo Nordisk INC | $58.09 | 2024 | Wegovy |
| Amgen INC. | $57.27 | 2024 | Repatha |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $49.81 | 2024 | Lifevest |
| Abbvie INC. | $39.55 | 2025 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $28.94 | 2025 | Amvuttra |
| Lexicon Pharmaceuticals, INC. | $25.65 | 2023 | Inpefa |
| Esperion Therapeutics, INC. | $15.77 | 2025 | Nexletol |
| Kiniksa Pharmaceuticals International, Plc | $14.20 | 2024 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Abu Sheikha listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.